002728.SHE Teyi Pharmaceutical Group Co Ltd
- Market cap
- CNY 4.68B
- P/E
- 70.2x
- P/B
- 2.48x
- ROE
- 3.7%
- Dividend yield
- 0.53%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 002728.SHE undervalued?
Graham number002728.SHE trades 178.1% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Teyi Pharmaceutical Group Co Ltd fundamental analysis
No fundamental analysis for Teyi Pharmaceutical Group Co Ltd yet.
Teyi Pharmaceutical Group Co Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Teyi Pharmaceutical Group Co Ltd
Teyi Pharmaceutical Group Co.,Ltd engages in the research and development, production, and sale of Chinese patented medicines, pharmaceutical preparations, raw materials, and products in the People's Republic of China. The company's products are used in respiratory system, cardiovascular and cerebrovascular, respiratory, cardiovascular, and digestive systems. The company was formerly known as Guangdong Taicheng Pharmaceutical Co., Ltd. and changed its name to Teyi Pharmaceut…
Full company profileTeyi Pharmaceutical Group Co Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Teyi Pharmaceutical Group Co Ltd annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 656M | 687M | 885M | 921M | 633M | 758M | 887M | 1.07B | 688M | 916M | 831M |
| Gross Profit | 313M | 331M | 520M | 547M | 302M | 402M | 435M | 599M | 301M | 466M | 474M |
| Operating Income | 100M | 117M | 182M | 198M | 58.2M | 141M | 197M | 293M | 24.1M | 78.0M | 83.2M |
| EBITDA | 155M | 174M | 260M | 289M | 148M | 228M | 278M | 370M | 92.3M | 147M | 84.3M |
| Net Income | 94.8M | 106M | 156M | 172M | 43.8M | 127M | 178M | 253M | 20.5M | 81.7M | 65.9M |
| EPS | 0.24 | 0.27 | 0.40 | 0.43 | 0.11 | 0.32 | 0.41 | 0.55 | 0.04 | 0.16 | 0.13 |
| Balance Sheet | |||||||||||
| Total Assets | 1.60B | 1.93B | 2.07B | 2.26B | 2.26B | 2.07B | 2.55B | 2.51B | 2.40B | 2.31B | 2.44B |
| Total Liabilities | 717M | 886M | 956M | 1.10B | 1.18B | 805M | 1.14B | 502M | 636M | 473M | 640M |
| Shareholders' Equity | 887M | 1.04B | 1.11B | 1.15B | 1.08B | 1.26B | 1.40B | 2.01B | 1.76B | 1.82B | 1.80B |
| Cash & Short-term Investments | 154M | 217M | 461M | 574M | 575M | 372M | 740M | 647M | 457M | 336M | 314M |
| Total Debt | 403M | 673M | 791M | 975M | 1.04B | 662M | 847M | 306M | 516M | 277M | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | 101M | 103M | 188M | 222M | 169M | 257M | 372M | 199M | -22.5M | 245M | - |
| Capital Expenditure | 171M | 40.6M | 152M | 131M | 89.4M | 110M | 90.3M | 86.0M | 114M | 79.5M | 64.0M |
| Free Cash Flow | -69.6M | 62.3M | 35.5M | 90.9M | 79.6M | 147M | 281M | 113M | -136M | 165M | 25.5M |
| Ratios | |||||||||||
| ROE | 10.7% | 10.2% | 14.0% | 14.9% | 4.1% | 10.1% | 12.7% | 12.6% | 1.2% | 4.5% | 3.7% |
| ROA | 5.9% | 5.5% | 7.5% | 7.6% | 1.9% | 6.1% | 7.0% | 10.1% | 0.9% | 3.5% | 2.7% |
| Net Profit Margin | 14.5% | 15.5% | 17.6% | 18.6% | 6.9% | 16.7% | 20.1% | 23.7% | 3.0% | 8.9% | 7.9% |
| Debt to Equity | 0.45x | 0.65x | 0.71x | 0.85x | 0.96x | 0.52x | 0.60x | 0.15x | 0.29x | 0.15x | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Teyi Pharmaceutical Group Co Ltd dividends
- Dividend yield
- 0.53%
- Forward dividend
- 0.15 CNY
- Payout ratio
- 30.5%
- Ex-dividend date
- Jun 18, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 24.9M | 0.05 | 30.5% |
| 2024 | CNY 182M | 0.36 | 889.5% |
| 2023 | CNY 149M | 0.32 | 58.9% |
| 2022 | CNY 148M | 0.34 | 82.8% |
| 2021 | CNY 138M | 0.34 | 109.0% |
| 2020 | CNY 164M | 0.42 | 374.2% |
| 2019 | CNY 150M | 0.37 | 87.3% |
| 2018 | CNY 118M | 0.30 | 76.2% |
| 2017 | CNY 31.9M | 0.08 | 30.0% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1.4:1 on Apr 24, 2024.
Who owns Teyi Pharmaceutical Group Co Ltd
- Insiders 40.46%
- Institutions 1.19%
- Public & others 58.34%
- Shares outstanding 513M
- Free float 267M
Teyi Pharmaceutical Group Co Ltd company profile
- Company name
- Teyi Pharmaceutical Group Co Ltd
- Ticker
- 002728.SHE
- ISIN
- CNE100001WK6
- Exchange
- Shenzhen Stock Exchange
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 1,434
- Fiscal year end
- December
- Address
- No. 9, 11, Changxing Road, Taishan, China, 529200
- Phone
- 86 75 0562 7588
- Website
- tczy.com.cn
About Teyi Pharmaceutical Group Co Ltd
Teyi Pharmaceutical Group Co.,Ltd engages in the research and development, production, and sale of Chinese patented medicines, pharmaceutical preparations, raw materials, and products in the People's Republic of China. The company's products are used in respiratory system, cardiovascular and cerebrovascular, respiratory, cardiovascular, and digestive systems. The company was formerly known as Guangdong Taicheng Pharmaceutical Co., Ltd. and changed its name to Teyi Pharmaceutical Group Co.,Ltd in November 2016. The company was founded in 2002 and is based in Taishan, the People's Republic of China.
Teyi Pharmaceutical Group Co Ltd management
5- Mr. Xiliang ChenCFO, Deputy GM & Director · born 1972
- Mr. Yongzhao ZhangDeputy General Manager · born 1982
- Mr. Wei Cheng WuDeputy General Manager · born 1969
- Mr. Wen Ge YanDeputy General Manager · born 1966
- Bi Jian CaiAccounting Supervisor